⚠️ This AI-generated report synthesizes publicly available information. AI can make mistakes. Please double check information in this report.
AstraZeneca PLC
Healthcare | Drug Manufacturers - General
⚡ Executive Summary
📊 The Bottom Line
AstraZeneca is a leading biopharmaceutical company known for its strong oncology portfolio and diverse pipeline. The company consistently invests in R&D, bringing innovative medicines to market globally. While facing intense competition, its broad therapeutic areas and strategic collaborations support a robust business model.
⚖️ Risk vs Reward
At a current price of US$183.60, AZN trades below the average analyst target of US$208.43, suggesting potential for upside. However, the stock is exposed to risks from R&D failures and patent expirations, which are balanced by a strong pipeline and diversified revenue streams, offering a moderate risk-reward profile.
🚀 Why AZN Could Soar
- • Continued success and expansion of the oncology portfolio, including new indications and market share gains for drugs like Tagrisso and Imfinzi, driving significant revenue growth.
- • Strategic diversification into new therapeutic areas and robust global market penetration, particularly in emerging markets, providing additional revenue streams and resilience.
- • Accelerated drug discovery and development through increased adoption of AI and advanced analytics, potentially improving R&D efficiency and success rates for pipeline assets.
⚠️ What Could Go Wrong
- • Significant pipeline failures in late-stage clinical trials or unexpected adverse events could impact future revenue streams and lead to substantial R&D write-offs.
- • Increased generic and biosimilar competition for key blockbuster drugs as patents expire, resulting in significant pricing pressure and erosion of market share.
- • Heightened global regulatory scrutiny and evolving healthcare policies could lead to stricter drug pricing controls and slower market access for new products, impacting profitability.
🏢 Company Overview
💰 How AZN Makes Money
- • AstraZeneca discovers, develops, manufactures, and commercializes a wide range of prescription medicines.
- • The company focuses on major therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology, and Rare Diseases.
- • Products are distributed globally to primary and specialty care physicians through direct sales forces, distributors, and local representative offices.
Revenue Breakdown
Oncology
40%
Treatments for various cancers, serving as a primary revenue driver.
Cardiovascular, Renal & Metabolic
20%
Medicines for heart, kidney, and metabolic conditions.
Rare Disease
16%
Specialty drugs addressing unmet medical needs in rare conditions.
Respiratory & Immunology
15%
Therapies for respiratory and autoimmune diseases.
Other
9%
Includes vaccines and other therapeutic areas not specifically categorized.
🎯 WHY THIS MATTERS
AstraZeneca's diversified portfolio across critical disease areas provides revenue stability and resilience against patent expirations in any single category. This strategy allows for sustained growth by addressing a broad spectrum of global medical needs.
⭐ Competitive Advantage: What Makes AZN Special
1. Deep R&D Pipeline and Innovation
AstraZeneca consistently invests heavily in research and development, maintaining a robust pipeline of novel medicines, particularly in oncology. This commitment allows the company to continuously introduce high-value drugs that address unmet medical needs, strengthening its market position and fostering long-term growth. Recent approvals highlight its innovative capacity.
2. Diversified Product Portfolio and Global Reach
With a broad range of products spanning oncology, CVRM, rare diseases, and respiratory & immunology, AstraZeneca reduces its reliance on any single drug. This diversification, combined with a strong global presence across key continents, mitigates regional market risks and provides stable, consistent revenue streams essential for a large biopharmaceutical company.
3. Strategic Collaborations and Acquisitions
AstraZeneca actively pursues strategic agreements and partnerships, such as those with Tempus for AI in oncology and CSPC Pharmaceutical Group for novel oral candidates. These collaborations enhance research capabilities, accelerate drug development, and expand market access, which are critical for sustaining innovation and competitive advantage in the fast-evolving pharmaceutical landscape.
🎯 WHY THIS MATTERS
These competitive advantages collectively enable AstraZeneca to maintain its leadership in the biopharmaceutical industry. A strong pipeline ensures future growth, while a diversified portfolio and global reach provide stability and market access essential for commercializing innovative treatments efficiently.
👔 Who's Running The Show
Pascal Claude Roland Soriot
CEO & Executive Director
Pascal Soriot, 66, has served as CEO since 2012, leading a significant transformation focused on scientific innovation and pipeline growth. Under his leadership, AstraZeneca has bolstered its oncology and rare disease franchises, driving substantial revenue growth and R&D productivity. He is a key architect of the company's long-term strategy and global expansion.
⚔️ What's The Competition
The biopharmaceutical industry is characterized by intense competition from global pharmaceutical giants, smaller biotech firms, and generic drug manufacturers. Competition primarily revolves around R&D innovation, patent protection, pricing, market access, and the ability to effectively commercialize new medicines across diverse therapeutic areas.
📊 Market Context
- Total Addressable Market - The global pharmaceutical market is projected to exceed US$2 trillion by 2026, driven by an aging population, rising chronic disease prevalence, and scientific advancements.
- Key Trend - The accelerating integration of artificial intelligence and machine learning into drug discovery and development processes, aiming to shorten timelines and improve success rates.
Competitor
Description
vs AZN
Pfizer Inc.
A major global pharmaceutical company known for its diverse portfolio, including vaccines, oncology, and internal medicine. Facing patent expirations on key drugs.
Pfizer has a broader vaccines portfolio, but AstraZeneca has a stronger focus on oncology and rare diseases. Pfizer's recent revenue has seen declines, unlike AZN's consistent growth.
Novartis AG
A Swiss multinational pharmaceutical company focusing on innovative medicines across various therapeutic areas, including cardiovascular, immunology, and oncology.
Novartis competes directly in several therapeutic areas, particularly oncology and cardiovascular diseases. Novartis showed strong sales growth and margin expansion in 2024.
Roche Holding AG
A Swiss multinational healthcare company with leading franchises in pharmaceuticals (oncology, immunology, ophthalmology) and diagnostics.
Roche is a global leader in oncology and diagnostics, creating strong competition for AstraZeneca's oncology segment. Roche has a significant presence in biotechnology.
Merck & Co., Inc.
An American multinational pharmaceutical company with strong positions in oncology (Keytruda), vaccines (Gardasil), and animal health.
Merck's blockbuster cancer immunotherapy Keytruda makes it a formidable competitor in oncology. AstraZeneca differentiates through a broader and more diversified oncology pipeline.
📊 Valuation & Analysis
📈 Wall Street Summary
Analyst Rating Distribution - 1 Hold, 6 Buy, 2 Strong Buy
1
6
2
12-Month Price Target Range
Low Target
US$120
-35%
Average Target
US$208
+14%
High Target
US$240
+31%
Closing: US$183.60 (20 Mar 2026)
🚀 The Bull Case - Upside to US$240
1. Oncology Portfolio Expansion
High Probability
Successful development and approval of new oncology indications, such as Imfinzi's approval in EU for gastric cancers, can significantly expand the addressable market and drive billions in new revenue, bolstering market leadership.
2. Rare Disease Growth Acceleration
Medium Probability
Robust growth in the rare disease portfolio, exemplified by new approvals and indications like Calquence for leukemia, provides a high-margin, less competitive revenue stream with substantial long-term growth potential.
3. Synergistic Collaborations and R&D Efficiency
Medium Probability
Leveraging strategic partnerships and AI in R&D, such as the collaboration with Tempus in oncology, can accelerate drug discovery, reduce development costs, and bring innovative treatments to market faster, enhancing profitability.
🐻 The Bear Case - Downside to US$120
1. Patent Expirations and Generic Competition
High Probability
The inevitable patent cliffs for key blockbuster drugs could expose AstraZeneca to significant revenue loss from generic and biosimilar competition, pressuring margins and requiring constant pipeline replenishment.
2. Clinical Trial Failures and Regulatory Setbacks
Medium Probability
Late-stage clinical trial failures or unexpected regulatory hurdles for pipeline assets can lead to substantial R&D write-offs, delayed product launches, and missed revenue targets, impacting investor confidence.
3. Increased Global Pricing Pressure
Medium Probability
Mounting pressure from governments and payers worldwide to reduce drug costs could lead to lower pricing for AstraZeneca's products, impacting overall revenue growth and profitability, especially in key markets.
🔮 Final thought: Is this a long term relationship?
For investors seeking durable growth in the biopharmaceutical sector, AstraZeneca presents a compelling long-term ownership proposition. Its robust and diversified pipeline, particularly in high-growth areas like oncology and rare diseases, positions it well to navigate industry challenges over the next decade. While continuous R&D investment and patent expiration risks are inherent, management's track record in fostering innovation and executing strategic collaborations suggests a resilient business capable of sustained value creation. However, the ability to consistently deliver breakthrough medicines and manage pricing pressures will be critical for maintaining its competitive edge.
📋 Appendix
Financial Performance
Metric
31 Dec 2025
31 Dec 2024
31 Dec 2023
Income Statement
Revenue
US$58.74B
US$54.07B
US$45.81B
Gross Profit
US$48.11B
US$43.87B
US$37.54B
Operating Income
US$13.33B
US$10.25B
US$8.72B
Net Income
US$10.22B
US$7.04B
US$5.96B
EPS (Diluted)
6.54
4.50
3.81
Balance Sheet
Cash & Equivalents
US$5.71B
US$5.49B
US$5.84B
Total Assets
US$114.07B
US$104.03B
US$101.12B
Total Debt
US$29.15B
US$30.11B
US$28.41B
Shareholders' Equity
US$48.67B
US$40.79B
US$39.14B
Key Ratios
Gross Margin
81.9%
81.1%
82.0%
Operating Margin
22.7%
19.0%
19.0%
Return on Equity
21.01
17.25
15.21
Analyst Estimates
Metric
Annual (31 Dec 2026)
Annual (31 Dec 2027)
EPS Estimate
US$5.18
US$5.97
EPS Growth
+13.1%
+15.3%
Revenue Estimate
US$63.2B
US$67.0B
Revenue Growth
+7.6%
+6.0%
Number of Analysts
3
3
Valuation Ratios
| Metric | Value | Description |
|---|---|---|
| P/E Ratio (TTM) | 28.07 | Measures the price investors are willing to pay for each dollar of earnings over the last twelve months, indicating market's earnings expectations. |
| Forward P/E | 30.76 | Indicates the price investors are willing to pay for each dollar of estimated future earnings, reflecting expectations for future profitability. |
| Price/Sales (TTM) | 4.85 | Calculates how much investors are paying for each dollar of revenue over the last twelve months, useful for valuing companies with inconsistent earnings. |
| Price/Book (MRQ) | 5.85 | Measures how much investors are willing to pay for each dollar of book value, indicating premium valuation relative to the company's net assets. |
| EV/EBITDA | 16.02 | Compares Enterprise Value to earnings before interest, taxes, depreciation, and amortization, often used to value companies by taking debt into account. |
| Return on Equity (TTM) | 22.84 | Measures the profitability of a company in relation to the equity invested by shareholders, indicating efficiency in generating profits from shareholder funds. |
| Operating Margin | 21.59 | Represents the percentage of revenue left after paying for operating expenses, indicating how efficiently a company is managing its core business operations. |
Peer Comparison
| Company | Market Cap (B) | P/E Ratio | P/B Ratio | Revenue Growth (%) | Operating Margin (%) |
|---|---|---|---|---|---|
| AstraZeneca PLC (Target) | 284.63 | 28.07 | 5.85 | 4.1% | 21.6% |
| Pfizer Inc. | 155.86 | 20.01 | 1.80 | -1.6% | 12.6% |
| Novartis AG | 302.91 | 17.79 | 6.40 | 9.6% | 28.9% |
| Roche Holding AG | 321.95 | 19.82 | 7.55 | 1.5% | 26.8% |
| Merck & Co., Inc. | 287.98 | 15.87 | 5.47 | 1.3% | 31.1% |
| Sector Average | — | 18.37 | 5.31 | 2.7% | 24.8% |